Hypothesis: Among children with first-episode, provoked, acute venous thrombosis, the effect of treatment duration on the risks of symptomatic recurrent VTE and clinically-relevant bleeding does not differ among subgroups treated sub-acutely with enoxaparin, dalteparin, fondaparinux, warfarin, oral direct factor Xa inhibitors, or oral direct thrombin inhibitors inhibitors.